Futura Medical plc has announced that the Mexican Secretariat of Health has granted marketing authorization for its topical gel formulation, Eroxon®, for the treatment of erectile dysfunction (ED). This authorization allows Eroxon® to be marketed in Mexico as an over-the-counter (OTC) treatment for ED without the need for a prescription. Eroxon® has a 10-minute onset of action and has been approved as an effective and clinically proven treatment for ED. The prevalence of ED affects at least 1 in 5 men globally, and Mexico has a population of 129 million.
Eroxon® has already been approved as the first pan-European clinically proven topical treatment for ED available OTC and is currently available in a growing number of EU and Middle East markets. The initial launches of Eroxon® began in March 2023 under the brand name Eroxon®, and commercial agreements have been made in key markets including the European Economic Area, UK, Switzerland, South Korea, Latin America, and the Middle East.
James Barder, the CEO of Futura, expressed excitement about the approval in Mexico, stating, "Mexico is a vibrant and dynamic market, and we look forward to bringing the benefits of Eroxon® to ED sufferers in Mexico with our commercial partner M8."
Futura Medical plc is a pharmaceutical company that develops innovative products based on its proprietary transdermal DermaSys® technology. The company's products are developed for the prescription and consumer healthcare markets, with a focus on maximizing product differentiation and value creation while minimizing risk. MED3000 is Futura's topical gel formulation for the treatment of ED, and Eroxon® is the brand name used in certain regions, such as the EU, for the clinically proven topical treatment for adult men with ED.